Emergence of Candida auris in Brazil in a COVID-19 Intensive Care Unit

Journal of Fungi

Magda M. de Miranda Costa¹  PedroH. Presta Dias²  Igor B. Brandão³  Regiane T. de Souza Jordão⁴  ArnaldoL. Colombo⁵  TheunT. de Souza de Groot⁵  FelicidadeM. Pereira⁶  JoãoN. de Almeida⁷  Elaine C. Francisco⁷  Ferry Hagen⁸ 

[1] Agência Nacional de Vigilância Sanitária, Brasília 71205-050, Brazil;Centro de Informações Estratégicas de Vigilância em Saúde, Salvador 40279-120, Brazil;Comissão de Controle de Infecção Hospitalar, Hospital de Bahia, Salvador 41810-011, Brazil;Coordenação Geral de Laboratórios de Saúde Pública, Ministério da Saúde, Brasília 70058-900, Brazil;Department of Medical Microbiology and Infectious Diseases, Canisius Wilhelmina Hospital (CWZ), 6532SZ Nijmegen, The Netherlands;Laboratório Central de Saúde Pública Professor Gonçalo Muniz, Salvador 40295-010, Brazil;Laboratório Especial de Micologia, Disciplina de Infectologia, Universidade Federal de São Paulo, São Paulo 04039-032, Brazil;Westerdijk Fungal Biodiversity Institute, 3508AD Utrecht, The Netherlands;

关键词: Candida auris;    COVID-19;    intensive care;    Brazil;   

DOI  :  10.3390/jof7030220

来源: DOAJ

【 摘 要 】

In December 2020, Candida auris emerged in Brazil in the city of Salvador. The first two C. auris colonized patients were in the same COVID-19 intensive care unit. Antifungal susceptibility testing showed low minimal inhibitory concentrations of 1 µg/mL, 2 µg/mL, 0.03 µg/L, and 0.06 µg/mL for amphotericin B, fluconazole, voriconazole, and anidulafungin, respectively. Microsatellite typing revealed that the strains are clonal and belong to the South Asian clade C. auris. The travel restrictions during the COVID-19 pandemic and the absence of travel history among the colonized patients lead to the hypothesis that this species was introduced several months before the recognition of the first case and/or emerged locally in the coastline Salvador area.

【 授权许可】

Unknown